Cannabis Compounds Show Promise in Tackling Widespread Liver Disease
New research emerging from Israel is offering a glimmer of hope for the millions worldwide grappling with a silent but serious liver condition. Scientists have identified two compounds naturally occurring in cannabis that show significant potential in improving metabolic dysfunction-associated steatotic liver disease (MASLD), a condition affecting approximately one-third of adults globally. In Australia, this translates to a substantial portion of the population potentially benefiting from these findings.
MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is characterised by the excessive accumulation of fat in the liver. While often asymptomatic in its early stages, it can progress to inflammation, scarring (fibrosis), and eventually liver damage, significantly impacting overall metabolic health.
Exploring the Therapeutic Potential of CBD and CBG
Researchers at the Hebrew University of Jerusalem focused their investigation on two non-psychoactive compounds found in cannabis: cannabidiol (CBD) and cannabigerol (CBG). Crucially, unlike tetrahydrocannabinol (THC), the well-known compound responsible for the “high” associated with cannabis, CBD and CBG do not induce such effects. This distinction is vital for their potential therapeutic application, allowing for the exploration of medicinal benefits without the associated cognitive impairment.
The groundbreaking study, published in the esteemed British Journal of Pharmacology, demonstrated that both CBD and CBG markedly reduced liver fat in experimental models. Furthermore, these compounds were found to enhance overall metabolic function, suggesting a multifaceted approach to combating MASLD.
Unravelling the Mechanism: Metabolic Remodelling in Liver Cells
The scientific team believes that these cannabis-derived compounds work by initiating a process termed “metabolic remodeling” within liver cells. Joseph Tam, the lead author of the study and director of the Multidisciplinary Center for Cannabinoid Research at Hebrew University, elaborated on the significance of their findings, stating, “Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function.”
This metabolic remodeling appears to involve a dual action:
- Boosting Cellular Energy: The compounds are observed to increase the levels of phosphocreatine, a crucial molecule that plays a vital role in supplying energy to cells, including those in the liver.
- Enhancing Detoxification: Simultaneously, CBD and CBG appear to stimulate enzymes responsible for the removal of harmful substances from the liver cells, contributing to a healthier cellular environment.
Important Caveats: Not a Licence for Recreational Use
It is imperative to understand that these promising findings do not equate to advocating for the smoking of cannabis for medicinal purposes. The researchers strongly caution that the observed benefits are linked to specific compounds, isolated and administered under controlled experimental conditions. The complex mix of compounds present in smoked cannabis, along with varying dosages and individual responses, means that recreational use is unlikely to yield the same therapeutic outcomes.
Indeed, separate research from McMaster University in Canada, published in the Canadian Journal of Psychiatry, has highlighted potential negative associations between THC use in younger individuals and increased risks of anxiety, depression, and suicidal ideation. Jillian Halladay, an assistant professor at McMaster University, noted that “Canadians who use cannabis tend to be more likely to meet criteria for anxiety and depressive disorders.” This underscores the critical difference between targeted, therapeutic intervention with specific compounds and general cannabis consumption.
The Road Ahead: Further Research and Clinical Trials
While the results are undeniably encouraging, the scientific community is emphasising the need for extensive further research. The next crucial step involves conducting rigorous clinical trials in humans to validate these findings and determine safe and effective dosages for MASLD treatment. Only then can the potential of CBD and CBG as a viable therapeutic option for millions suffering from this prevalent liver disease be fully realised. The journey from laboratory discovery to patient treatment is often a long one, but these initial steps offer a significant ray of hope.
